Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560047 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL14999866 | 0.85 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4ETDP1 | |
| SCHEMBL3166616 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HRH3KDM4EMEN1KMT2A | |
| SCHEMBL4521742 | 0.80 | TSHR (0.52) | ALDH1A1HRH3KDM4ETDP1 | |
| SCHEMBL30340989 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HRH3HTTKDM4E | |
| SCHEMBL22307651 | 0.79 | ALDH1A1 (0.51) | ALDH1A1HRH3KDM4EMEN1KMT2A | |
| SCHEMBL2108519 | 0.78 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2HRH3HTTKDM4E | |
| SCHEMBL3568406 | 0.77 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2KDM4ETDP1MEN1 | |
| SCHEMBL922442 | 0.77 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2KDM4ETDP1MEN1 | |
| SCHEMBL247593 | 0.77 | VCAM1 (0.56) | ALDH1A1SMN1; SMN2HRH3KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035770-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2017-09-21 | — | — | US | disclosed |
| US-9643925-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED | 2017-05-09 | — | — | US | disclosed |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2016-04-28 | — | — | US | disclosed |
| US-9150564-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED | 2015-01-01 | — | — | US | disclosed |
| US-8871769-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871768-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | CYTOKINETICS, INCORPORATED (US) | 2014-02-06 | — | — | US | disclosed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | ALDH1A1 3361/4885SMN1; SMN2 1643/4885HRH3 2219/4885 |
| US-20170267638-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885SMN1; SMN2 676/4885HRH3 3208/4885 |
| US-20140038983-A1 | UREAS AND THEIR USE IN THE TREATMENT OF HEART FAILURE | TNNI3, TNNT2, MYLK2 | ALDH1A1 3361/4885SMN1; SMN2 1643/4885HRH3 2219/4885 |
| US-20150005296-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885SMN1; SMN2 676/4885HRH3 3208/4885 |
| US-20160115133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885SMN1; SMN2 676/4885HRH3 3208/4885 |
| US-10035770-B2 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | ALDH1A1 4381/4885SMN1; SMN2 676/4885HRH3 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.